List of Excipients in Branded Drug KALYDECO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Vertex Pharmaceuticals Incorporated	KALYDECO	ivacaftor	51167-200	AMMONIA	2030-02-13
Vertex Pharmaceuticals Incorporated	KALYDECO	ivacaftor	51167-200	CARNAUBA WAX	2030-02-13
Vertex Pharmaceuticals Incorporated	KALYDECO	ivacaftor	51167-200	CELLULOSE, MICROCRYSTALLINE	2030-02-13
Vertex Pharmaceuticals Incorporated	KALYDECO	ivacaftor	51167-200	CROSCARMELLOSE SODIUM	2030-02-13
Vertex Pharmaceuticals Incorporated	KALYDECO	ivacaftor	51167-200	FD&C BLUE NO. 2	2030-02-13

KALYDECO Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 17, 2026

KALYDECO (ivacaftor) uses a conventional immediate-release oral formulation built around lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide, and magnesium stearate. The formulation is commercially mature, but opportunities remain in pediatric delivery, lactose-free excipient systems, taste masking, global supply, and lower-cost generic manufacturing. KALYDECO is a small-molecule drug, so biosimilar competition does not apply. Generic and authorized-generic entry depend on active patent and regulatory exclusivity data in each jurisdiction.

What excipients are used in KALYDECO tablets and oral granules?

FDA labeling identifies substantially similar core excipient systems for KALYDECO tablets and oral granules. The dosage forms differ mainly in manufacturing format, dose flexibility, and administration requirements.

Dosage form	Active ingredient	Key excipients identified in FDA labeling	Commercial function
150 mg film-coated tablet	Ivacaftor	Lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide, magnesium stearate	Dilution, compression, disintegration, wetting, glidancy, lubrication
50 mg oral granules	Ivacaftor	Lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide, magnesium stearate	Dose flexibility and pediatric administration
75 mg oral granules	Ivacaftor	Lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide, magnesium stearate	Dose flexibility and pediatric administration

The film coating for the tablet contains standard coating materials, including hypromellose-based film-forming components and colorants. Exact composition can vary by manufacturing site and product presentation, so the current FDA-approved labeling and CMC documentation control the applicable formulation record. [1]

KALYDECO is administered with fat-containing food. This requirement relates primarily to ivacaftor’s solubility and exposure profile rather than to a unique proprietary excipient platform. The product therefore depends on patient administration instructions as part of its overall bioavailability strategy. [1]

Why does KALYDECO use lactose, cellulose, croscarmellose, and sodium lauryl sulfate?

The excipient system is designed for robust tablet compression and rapid disintegration rather than modified release.

Lactose monohydrate

Lactose provides bulk and improves powder-handling characteristics. It is a common diluent in oral solid dosage forms and can support tablet weight and content uniformity at relatively low active-drug loading.

Its presence creates a commercial constraint for patients with lactose intolerance, galactose metabolism disorders, or other dairy-related excipient restrictions. Lactose exposure in a small tablet or granule dose may be limited, but the excipient remains relevant for label differentiation and patient access.

Microcrystalline cellulose

Microcrystalline cellulose contributes binding, compactibility, and tablet mechanical strength. It is also useful in direct-compression systems, which can reduce process complexity compared with wet granulation.

For generic manufacturers, microcrystalline cellulose is unlikely to create a meaningful intellectual-property barrier. The commercial issue is supplier qualification, particle-size control, and consistent compression performance.

Croscarmellose sodium

Croscarmellose sodium is a superdisintegrant. It promotes rapid liquid penetration and tablet breakup, supporting immediate release of ivacaftor.

A generic applicant can use a different superdisintegrant or a different level of croscarmellose sodium if the finished product meets applicable quality and bioequivalence requirements. The relevant risks are dissolution, content uniformity, and mechanical integrity rather than ownership of the excipient itself.

Sodium lauryl sulfate

Sodium lauryl sulfate functions as a wetting agent and can improve dispersion of a poorly water-soluble active ingredient. It may be important for dissolution reproducibility, especially where particle-size distribution and drug wetting affect release.

Sodium lauryl sulfate is a potential formulation redesign target because some manufacturers seek lower-surfactant systems or alternatives with improved tolerability and supply characteristics. Any substitution would require comparative dissolution and bioequivalence support.

Colloidal silicon dioxide and magnesium stearate

Colloidal silicon dioxide improves powder flow. Magnesium stearate reduces friction during compression and ejection.

Both are standard, low-cost excipients. Their process impact can still be material. Over-lubrication with magnesium stearate can reduce tablet hardness or slow dissolution, while inadequate glidant control can affect weight variation and content uniformity.

What formulation opportunities exist for KALYDECO competitors?

The strongest opportunities are in patient usability and manufacturing efficiency, not in creating a new therapeutic mechanism.

Lactose-free ivacaftor formulations

A lactose-free tablet or granule product could address patients who cannot use lactose-containing products. Candidate diluents include mannitol, dibasic calcium phosphate, starch-derived materials, and selected co-processed excipients.

The commercial value depends on whether the product offers a meaningful labeling or access advantage. A lactose-free formulation would need to preserve:

• Ivacaftor assay and content uniformity
• Immediate-release dissolution
• Stability under intended storage conditions
• Acceptable tablet size or granule mass
• Bioequivalence to the reference product

A lactose-free product could be pursued through an abbreviated application if it meets the applicable product and bioequivalence requirements. A materially different formulation or delivery system could require a different regulatory pathway.

Taste-masked pediatric granules

The oral granule presentation is the most important formulation opportunity because KALYDECO is used in young children. A competitor could target:

• Reduced bitterness
• Lower grittiness
• Better suspension or food-mixing performance
• Smaller sachet volume
• Improved moisture protection
• More flexible dose preparation

Taste masking may use polymer coating, lipid coating, ion-exchange technology, complexation, or particulate encapsulation. The key constraint is that taste-masking materials cannot materially impair ivacaftor release or create dose nonuniformity when mixed with soft food or liquid.

A granule product with improved palatability may have commercial value even if the active ingredient, dose, and indication are unchanged. The opportunity is strongest in markets where pediatric adherence and caregiver administration are important purchasing factors.

Alternative wetting systems

Sodium lauryl sulfate can be replaced or supplemented by other surfactants or wetting technologies. Potential approaches include:

• Poloxamers
• Sodium stearyl fumarate-based systems
• Lecithin or phospholipid systems
• Particle-size reduction
• Amorphous solid dispersions
• Spray-dried or engineered drug particles

These approaches may reduce dependence on a single surfactant or improve dissolution robustness. They also create higher CMC and scale-up risk than a conventional excipient substitution.

Multiparticulate and sprinkle formats

A multiparticulate formulation could improve dose flexibility for children who cannot swallow tablets. It could also support administration through soft food without requiring swallowing of a whole dosage unit.

The main technical risks are segregation, powder loss during administration, moisture sensitivity, food compatibility, and dose recovery. A new sprinkle formulation could be protected by formulation, coating, particle-size, or administration-method claims even where the active compound is no longer broadly protected.

What patents protect KALYDECO and its formulation?

KALYDECO’s primary protection has historically centered on ivacaftor compound and use patents rather than on the basic excipients. The exact enforceable estate depends on patent-term adjustment, patent-term extension, pediatric exclusivity, terminal disclaimers, Orange Book listings, and jurisdiction.

Protection category	Relevance to KALYDECO	Competitive implication
Ivacaftor compound patents	Protect the active chemical entity and related compounds	Principal barrier to early generic entry
Method-of-use patents	Cover treatment of cystic fibrosis patients with specified CFTR mutations or clinical conditions	May constrain labeling and carved-out generic indications
Formulation patents	May cover specific solid forms, compositions, particle properties, or release profiles	Relevant to differentiated generic and 505(b)(2) strategies
Manufacturing patents	May cover synthesis, purification, crystallization, or process controls	Can raise API sourcing and freedom-to-operate issues
Pediatric or dosage-form patents	May cover granules, age-specific dosing, or administration methods	Most relevant to pediatric competitors
Regulatory exclusivity	FDA exclusivity is separate from patent rights	Can delay approval even after patent expiry

The FDA Orange Book is the controlling public source for listed U.S. patents and use codes. Patent status should be assessed by patent number and claim scope, not by the presence of a product name alone. [2]

Excipients such as lactose, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate are established generic materials. Their use in KALYDECO is unlikely to create stand-alone exclusivity. A formulation patent would need to claim a sufficiently specific composition, process, particle structure, stability profile, or clinical-use relationship.

When does KALYDECO lose exclusivity?

KALYDECO lost the commercial protection associated with early small-molecule launch exclusivity years after its 2012 FDA approval, but patent expiration and generic launch timing remain jurisdiction-specific.

The relevant U.S. questions are:

1. Which ivacaftor patents remain listed in the Orange Book?
2. Which claims cover the proposed generic’s labeling and formulation?
3. Has an ANDA applicant submitted a Paragraph IV certification?
4. Has Vertex initiated patent litigation within the statutory period?
5. Does the reference product retain any unexpired regulatory exclusivity?
6. Are pediatric, method-of-use, or formulation claims relevant to the proposed product?

A generic company can challenge listed patents through a Paragraph IV certification. If the patent holder sues within the statutory period, FDA approval may be subject to a 30-month stay, subject to litigation developments and statutory exceptions. [3]

Because KALYDECO is a small molecule, the principal generic risk is an ANDA or, for a differentiated product, a 505(b)(2) application. Biosimilar applications under the Public Health Service Act are not relevant.

What is the Orange Book status of KALYDECO?

The Orange Book identifies approved drug products, therapeutic-equivalence evaluations, patent listings, and exclusivity information for FDA-approved products. KALYDECO’s Orange Book analysis should separate:

• The 150 mg tablet
• The 50 mg granules
• The 75 mg granules
• Any listed patents tied to the reference drug
• Use codes associated with CFTR mutation populations
• Current marketing status and listed strengths

An ANDA applicant may seek approval for all or only selected strengths and dosage forms. A pediatric granule competitor faces a different development burden from a 150 mg tablet competitor because the granules create additional performance requirements around taste, food mixing, dose recovery, and administration.

The strategic value of the Orange Book listing is greatest when a patent claim covers a commercially necessary feature. A narrow use patent may be avoidable through a label carve-out. A formulation patent may be more difficult to avoid if the reference product’s release, strength, or administration characteristics are central to the approved product.

Which companies are challenging KALYDECO exclusivity?

KALYDECO is marketed by Vertex Pharmaceuticals. Public competitive pressure is more likely to arise from generic drug manufacturers, specialty pharmaceutical companies, and companies developing alternative CFTR modulators than from biosimilar developers.

Potential challenger categories include:

• Large generic manufacturers pursuing ivacaftor ANDAs
• Specialty companies developing pediatric or lactose-free formulations
• API manufacturers seeking non-infringing ivacaftor processes
• Companies offering authorized-generic or licensing arrangements
• Developers of next-generation CFTR modulators that reduce reliance on ivacaftor monotherapy

A definitive list of current Paragraph IV challengers requires the latest FDA filings, litigation dockets, and company disclosures. Publicly reported challenge activity should be distinguished from routine ANDA filing, which may not become visible until litigation or regulatory action occurs.

What patent litigation and settlement issues affect KALYDECO?

KALYDECO litigation risk has two distinct dimensions.

Patent litigation

Patent litigation may involve:

• Ivacaftor compound claims
• Combination treatment claims
• Patient-selection or mutation-specific uses
• Pediatric formulations
• Solid-state or manufacturing claims
• Infringement allegations based on generic labeling

The commercial impact depends on the asserted claims and the proposed generic’s design. A successful label carve-out may eliminate some method-of-use exposure but does not address compound or formulation claims.

Settlement agreements

A patent settlement may provide a generic company with a licensed entry date, an authorized-generic arrangement, or other commercial rights. Settlement terms are often confidential, while certain filing and review documents may become public through FDA or court records.

For forecasting purposes, the critical terms are:

• Generic launch date
• Authorized-generic rights
• Product strengths covered
• Geographic scope
• Royalty or supply obligations
• Restrictions on pediatric or formulation products

How strong is the KALYDECO patent estate?

KALYDECO’s patent estate is strongest where it protects the active compound or a commercially unavoidable product characteristic. It is weaker where protection relies on a narrow method-of-use claim that can be removed from a generic label.

Patent subject	Relative strength against generic entry	Reason
Ivacaftor compound	High during enforceable term	Difficult to design around while retaining the same active ingredient
Basic excipient composition	Low	Standard excipients are readily substitutable
Specific granule technology	Moderate to high	Depends on claim breadth and technical necessity
Mutation-specific method of use	Moderate	May be avoidable through labeling strategy
Manufacturing process	Variable	Strong if process is difficult to replace or API purity is difficult to match
Taste-masking technology	Moderate	Can be avoided through a different delivery design

The practical strength of the estate is therefore not determined by patent count. It depends on whether a challenger can produce an equivalent ivacaftor product without practicing an enforceable claim.

What generic launch risks exist for KALYDECO?

Generic entry could occur in several forms:

Full-strength tablet entry

A 150 mg tablet is the most straightforward generic target. Development would focus on dissolution, bioequivalence, stability, and commercial-scale compression.

Pediatric granule entry

Granules create a more differentiated opportunity but also a higher development burden. A generic applicant must address taste, food mixing, dose uniformity, sachet packaging, and age-appropriate administration.

Partial-strength or alternative-dose entry

A manufacturer may enter selected strengths first, particularly where demand, manufacturing economics, or patent exposure differs by presentation.

Authorized-generic entry

An authorized generic could reduce price erosion while allowing the originator to retain supply-chain control. This strategy is more commercially relevant when independent generic entry is imminent or when pediatric access is a priority.

Vertex’s broader cystic fibrosis franchise also affects KALYDECO economics. Patients may receive combination regimens involving ivacaftor, tezacaftor, or elexacaftor, which can reduce the standalone market for KALYDECO while preserving demand for ivacaftor in mutation-specific or age-specific populations. [4]

What commercial opportunities exist for KALYDECO excipients and manufacturing?

The largest opportunities are in formulation replacement, pediatric convenience, and supply-chain localization.

Excipient supply

Suppliers can target qualified sources for:

• Pharmaceutical-grade lactose monohydrate
• Direct-compression microcrystalline cellulose
• Low-substitution or high-performance croscarmellose sodium
• Surfactants and wetting agents
• Colloidal silicon dioxide
• Magnesium stearate
• Film-coating systems
• Moisture-barrier sachet materials

The value proposition is supply continuity, not exclusivity. Dual sourcing, regional manufacturing, and tighter particle-size specifications may be commercially important to generic producers.

Co-processed excipients

Co-processed excipients could simplify manufacture by combining binding, flow, and disintegration functions. They may reduce process steps or improve granule uniformity, but they require comparative dissolution and stability work.

Pediatric packaging

Single-dose sachets with improved moisture protection, easier opening, and lower powder retention can create a meaningful product advantage. Packaging patents may protect the delivery system even where the excipient composition is conventional.

Global formulations

KALYDECO’s commercial opportunity differs by market. Higher-income markets may prioritize lactose-free and pediatric convenience features. Emerging markets may prioritize low-cost tablets, local API supply, and stable room-temperature packaging.

Geographic freedom to operate must be assessed independently because patent term, patent validation, compulsory licensing rules, regulatory pathways, and reference-product requirements vary by country.

How does KALYDECO compare with other CFTR modulators?

Product	Active ingredients	Commercial role	Excipient opportunity
KALYDECO	Ivacaftor	Mutation-specific CFTR potentiator; pediatric granules and tablets	Lactose-free granules, taste masking, low-cost generic tablet
ORKAMBI	Lumacaftor/ivacaftor	Combination CFTR modulator	Fixed-dose combination dissolution and tablet-size optimization
SYMDEKO	Tezacaftor/ivacaftor	Combination CFTR modulator	Combination-product manufacturing and pediatric delivery
TRIKAFTA/KAFTRIO	Elexacaftor/tezacaftor/ivacaftor	Broad CFTR modulator regimen	Combination-tablet process control and future pediatric forms

KALYDECO has the clearest formulation opportunity in pediatric granules and mutation-specific access. Combination products have greater clinical and commercial scale but often present more difficult formulation and intellectual-property barriers.

Key Takeaways

• KALYDECO uses a conventional immediate-release excipient platform centered on lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide, and magnesium stearate.
• The highest-value formulation opportunities are lactose-free products, better-tasting pediatric granules, alternative wetting systems, and improved sachet packaging.
• Excipients themselves are unlikely to provide meaningful exclusivity. Patent value lies in specific formulations, delivery systems, manufacturing processes, or method-of-use claims.
• KALYDECO faces generic rather than biosimilar risk because ivacaftor is a small molecule.
• A 150 mg tablet is the simplest generic target. Pediatric granules offer greater differentiation but carry more CMC and usability risk.
• The FDA Orange Book, current patent records, Paragraph IV filings, and litigation dockets determine the practical U.S. entry timeline.
• Vertex’s combination CFTR products reduce standalone KALYDECO exposure while preserving demand in specific mutation and pediatric segments.

FAQs About KALYDECO Excipients and Commercial Strategy

Does KALYDECO contain lactose?

Yes. FDA labeling identifies lactose monohydrate in KALYDECO tablets and oral granules. This creates a potential differentiation opportunity for lactose-free ivacaftor products.

Can a generic manufacturer use different excipients from KALYDECO?

Yes. A generic manufacturer can generally use a different excipient system if the product satisfies FDA requirements for pharmaceutical equivalence, bioequivalence, quality, stability, and labeling.

Is KALYDECO suitable for a biosimilar application?

No. Ivacaftor is a small molecule. Competitive products would normally use an ANDA or, where appropriate, a 505(b)(2) pathway rather than a biosimilar application.

What is the most attractive pediatric opportunity for ivacaftor?

Taste-masked, lactose-free oral granules with strong moisture protection and simple food-mixing instructions offer the clearest pediatric product opportunity.

Can an excipient supplier patent a KALYDECO replacement formulation?

An excipient supplier may participate in a patentable formulation, process, particle, coating, or packaging invention. The use of standard excipients alone generally does not create strong proprietary protection.

References

1. U.S. Food and Drug Administration. (2024). KALYDECO (ivacaftor) tablets and oral granules: Prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
3. U.S. Food and Drug Administration. (2017). ANDA submissions: Refuse-to-receive standards guidance for industry.
4. Vertex Pharmaceuticals Incorporated. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.